“One of the important reasons that we use Waters LC-MS instruments is that beyond the quality of the products, Waters delivers a high degree of technical training. This provides us with the knowledge and confidence that we can solve our complex research questions.” comments Triskelion’s Richard Bas.
“If You Build it, He Will Come” Urged on by a voice no one else could hear, Ray Kinsella, played by Kevin Costner in the movie Field of Dreams, cleared a few acres of corn… Read more >
In biotherapeutics, the state of glycosylation has a direct and pronounced effect of the structure, stability, serum half-life, immunogeneicity and bioactivity of the molecule, and constitutes a critical quality attribute (CQA). In our study, characterizing and comparing the glycosylation profile of infliximab began by examining the glycosylation profiles from intact and reduced subunit mass data.
Advancements in High-Resolution Analytics for Characterization of Innovator and Biosimilar Therapeutics Part 2: Peptide Analysis of Infliximab
Advancements in High-Resolution Analytics for the Characterization of Innovator and Biosimilar Therapeutics As the pharmaceutical industry continues to evolve its focus from small-molecule drugs to balanced product portfolios that include protein therapeutics, analytical chemists are… Read more >
Microflow or nanoflow chromatography has been used mostly in the academic and fundamental research environment in the past for its various advantages over analytical liquid chromatography, but rarely in the industrial settings. This is most… Read more >
Dr. Erin Chambers is a Director in the Scientific Operations group at Waters Corporation. She recently served as a judge for the Bioanalysis Zone New Investigator Award. I sat down with Erin to gauge her… Read more >
This past May, many of the nation’s leading bioanalysts gathered in New England to share ideas and explore the latest advances in mass spectrometry, liquid chromatography, and sample preparation for large molecule quantification. At Waters’… Read more >
Oligonucleotide drug development has seen its share of ups and downs over the past 20 years – but why? The promise of antisense oligonucleotides (ASOs) and later small interfering oligonucleotides (siRNAs) as therapeutics that can… Read more >
Congratulations are in order as the University of Birmingham is the most recent university to expand the footprint of metabolic phenotyping research centres around the world. As state-of-the-art metabolic phenotyping facilities able to conduct small-scale… Read more >